Cellectis (NASDAQ:CLLS) Earns Sell Rating from Analysts at StockNews.com

StockNews.com initiated coverage on shares of Cellectis (NASDAQ:CLLS) in a research note published on Friday morning. The firm issued a sell rating on the biotechnology company’s stock.

Other analysts also recently issued reports about the stock. Oppenheimer decreased their target price on shares of Cellectis from $11.00 to $10.00 and set an outperform rating for the company in a research report on Wednesday, June 12th. JMP Securities reiterated a market outperform rating and set a $6.00 price target on shares of Cellectis in a research note on Friday, May 31st.

Cellectis Trading Up 0.5 %

NASDAQ CLLS opened at $2.08 on Friday. The company has a current ratio of 1.63, a quick ratio of 1.63 and a debt-to-equity ratio of 0.69. Cellectis has a 1-year low of $0.96 and a 1-year high of $3.77. The firm’s fifty day simple moving average is $2.14 and its 200-day simple moving average is $2.54. The company has a market capitalization of $115.61 million, a PE ratio of -1.61 and a beta of 3.10.

Cellectis (NASDAQ:CLLS) last posted its quarterly earnings results on Tuesday, May 28th. The biotechnology company reported ($0.15) earnings per share for the quarter. The firm had revenue of $6.50 million for the quarter. Cellectis had a negative return on equity of 67.41% and a negative net margin of 529.81%. As a group, sell-side analysts anticipate that Cellectis will post -0.54 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Cellectis stock. Baillie Gifford & Co. boosted its holdings in shares of Cellectis S.A. (NASDAQ:CLLS) by 1.3% in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 827,248 shares of the biotechnology company’s stock after purchasing an additional 10,605 shares during the quarter. Baillie Gifford & Co. owned about 1.49% of Cellectis worth $2,192,000 at the end of the most recent quarter. 63.90% of the stock is owned by hedge funds and other institutional investors.

About Cellectis

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.